FDAClass IIJune 14, 2023

Buprenorphine Sublingual Tablets recall: CGMP Deviations

Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.

Why was Buprenorphine Sublingual Tablets recalled?

CGMP Deviations

What should I do if I have this product?

Review the official FDA enforcement record for current instructions.

What to do with a recalled product: refunds, receipts, safe disposal and how to report a problem.

Is my product affected?

Compare the item in your hand with every identifier below from the official FDA record. Only products that match the listed product and lot, UPC or model codes are part of this recall.

Which lot codes, UPCs or models are affected?

Lot #: DND1515A, Exp 08/24

Product
Buprenorphine Sublingual Tablets, 8 mg, 30 count-bottles, Rx only, Manufactured by: Sun Pharma, NDC 62756-460-83.
Recalling firm
SUN PHARMACEUTICAL INDUSTRIES INC
Quantity
12,336 bottles
Distribution
Product was distributed to 19 distributors nationwide.
Recall date
June 14, 2023
Classification
Class II
Status
Terminated
Agency
FDA (drug)
Open FDA enforcement record Latest recalls